WTNPA Feb 12th

Vertex Pharmaceuticals Medical Science Liaison is scheduled for Feb 12th at 6:00 , Program: The Role of Selective Inhibition of NaV 1.8 and Suzetrigine in Managing Acute Pain.  Location: Flat Iron Grill. Encourage everyone to RSVP as soon as possible.  Please help support our monthly meetings so we will be able to continue to get sponsors for our monthly meeting.  We have the opportunity to learn about disease states, medications and how to use them.  Monthly meetings are a wonderful way to collaborate within your profession. 

Vertex Pharmaceuticals primarily develops transformative medicines for serious genetic diseases, most famously cystic fibrosis (CF), with blockbusters like Trikafta, Kalydeco, Orkambi, and Symdeko that treat the underlying cause, alongside newer therapies for blood disorders (Casgevy for sickle cell/thalassemia) and pain (Journavx, VX-548 in trials). Their strategy focuses on fixing causal biology, expanding from CF to other areas like kidney disease, diabetes, and neuropathic pain.